Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

PURPOSE: To determine the role and rational application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant non-small-cell lung cancer (NSCLC). METHOD: Randomized controlled trials (RCTs) that compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shu-Ling, Yi, Xiao-Fang, Huang, Le-Tian, Sun, Li, Ma, Jie-Tao, Han, Cheng-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391763/
https://www.ncbi.nlm.nih.gov/pubmed/37528390
http://dx.doi.org/10.1186/s12885-023-11194-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391763/
https://www.ncbi.nlm.nih.gov/pubmed/37528390
http://dx.doi.org/10.1186/s12885-023-11194-6

Ejemplares similares